Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early phase 2 study of AKP-009 in benign prostatic hyperplasia
jRCT2080224995Phase 2Completed
- Sponsor
- ASKA Pharmaceutical Holdings Co., Ltd.
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ludaterone acetate in benign prostatic hyperplasia (BPH) (4 arms), sponsored by ASKA Pharmaceutical Holdings Co., Ltd. Primary endpoint: Percent change from baseline in prostate volume at Week 12. Started Dec 2019; status: completed.
02
Drugs
ludaterone acetate
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on jRCT2080224995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224995.